AbbVie Stock News

Nine women from across the U.S. share their personal experiences with breast augmentation and reconstruction with Natrelle® – celebrating confidence, self-expression, and restoration. IRVINE, Calif.

AbbVie (ABBV 0.17%) reported second quarter 2025 results on July 31, 2025, delivering adjusted EPS of $2.97 (up $0.11 from guidance midpoint) and net revenues of $15.4 billion (up $400 million from expectations).

Spoiler: You would have done well -- and even better if you'd reinvested your dividends.

The "it" factor. Some stocks have it.

What does it take to be a Dividend Champion? A company must increase its dividend for at least 25 consecutive years for its stock to make the list.

A bellwether stock in the lately rather up-and-down pharmaceutical sector, AbbVie (ABBV 3.31%) finished the trading week in style. The company's shares closed more than 3% higher in price thanks in no small part to a clutch of post-earnings analyst price-target increases.

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Great businesses have a habit of remaining so even when market volatility arises. The stock market is cyclical, and ups as well as downs are inevitable.